NasdaqGS - Nasdaq Real Time Price USD
argenx SE (ARGX)
At close: 4:00 PM EST
After hours: 4:08 PM EST
Research Analysis
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 14 | 6 | 16 | 17 |
| Avg. Estimate | 1.06 | 1.61 | 1.92 | 8.45 |
| Low Estimate | -0.62 | 0.06 | 0.14 | 1.32 |
| High Estimate | 2.17 | 2.29 | 3.03 | 12.72 |
| Year Ago EPS | -1.55 | -0.97 | -4.76 | 1.92 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 19 | 9 | 29 | 29 |
| Avg. Estimate | 613.67M | 645.28M | 1.97B | 2.91B |
| Low Estimate | 526.76M | 578.22M | 1.59B | 2.13B |
| High Estimate | 667.91M | 703.4M | 2.05B | 3.69B |
| Year Ago Sales | 385.67M | 383.84M | 1.17B | 1.97B |
| Sales Growth (year/est) | 59.12% | 68.11% | 68.40% | 47.62% |
Earnings History
| CURRENCY IN USD | 12/31/2023 | 3/31/2024 | 6/30/2024 | 9/30/2024 |
|---|---|---|---|---|
| EPS Est. | -1.16 | -0.81 | -0.99 | 0.06 |
| EPS Actual | -1.55 | -0.97 | 0.41 | 1.28 |
| Difference | -0.39 | -0.16 | 1.41 | 1.22 |
| Surprise % | -33.28% | -19.93% | 141.80% | 2,138.78% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 1.06 | 1.61 | 1.92 | 8.45 |
| 7 Days Ago | 1.04 | 1.62 | 1.73 | 8.16 |
| 30 Days Ago | 0.49 | 0.95 | -0.1 | 5.79 |
| 60 Days Ago | 0.45 | 0.99 | 0.27 | 6.05 |
| 90 Days Ago | 0.48 | 0.84 | 0.29 | 5.82 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 9 | 3 | 13 | 12 |
| Up Last 30 Days | 8 | 1 | 10 | 10 |
| Down Last 7 Days | 2 | 1 | -- | 1 |
| Down Last 30 Days | 2 | 1 | 1 | 2 |
Growth Estimates
| CURRENCY IN USD | ARGX | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 168.34% | -- | -- | 5.00% |
| Next Qtr. | 265.87% | -- | -- | 12.00% |
| Current Year | 140.24% | -- | -- | 2.10% |
| Next Year | 340.71% | -- | -- | 12.20% |
Upgrades & Downgrades
| Reiterates | Oppenheimer: Outperform to Outperform | 11/21/2024 |
| Maintains | Evercore ISI Group: Outperform to Outperform | 11/21/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 11/20/2024 |
| Upgrade | Wolfe Research: Peer Perform to Outperform | 11/12/2024 |
| Upgrade | Scotiabank: Sector Perform to Sector Outperform | 11/5/2024 |
| Maintains | JP Morgan: Overweight to Overweight | 11/4/2024 |
Related Tickers
ALNY Alnylam Pharmaceuticals, Inc.
244.89
-0.77%
ASND Ascendis Pharma A/S
129.81
+5.85%
PCVX Vaxcyte, Inc.
88.54
+0.17%
BGNE BeiGene, Ltd.
190.51
-2.08%
IMVT Immunovant, Inc.
26.87
+1.24%
NAMS NewAmsterdam Pharma Company N.V.
20.20
+0.40%
MDGL Madrigal Pharmaceuticals, Inc.
347.45
+5.53%
CYTK Cytokinetics, Incorporated
49.10
+3.00%
BPMC Blueprint Medicines Corporation
94.15
-2.56%
PTGX Protagonist Therapeutics, Inc.
46.46
+11.55%